Comparative Pharmacology
Head-to-head clinical analysis: PONLIMSI versus TASIGNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PONLIMSI versus TASIGNA.
PONLIMSI vs TASIGNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the activity of BCR-ABL, the constitutively activated fusion protein responsible for chronic myeloid leukemia (CML). It also inhibits other kinases including KIT, PDGFR, and DDR1.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
400 mg orally twice daily approximately every 12 hours. Administer on an empty stomach (no food for at least 2 hours before and 1 hour after dose). Swallow whole with water; do not crush or chew.
None Documented
None Documented
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Terminal elimination half-life is approximately 90-120 hours, supporting once-daily dosing.
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Primarily fecal (approximately 66-93% of the dose) as unchanged drug and metabolites; renal excretion is minimal (<5% of the dose).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor